CONCLUSIONS	Despite nonsignificant changes for the primary endpoint of average vessel TBR , HD losmapimod reduced vascular inflammation in the most inflamed regions , concurrent with a reduction in inflammatory biomarkers and FDG uptake in visceral fat .\